Dr. Guido Ferrari, MD, is an Associate Professor at Duke University in the Department of Surgery and Molecular Genetics and Microbiology. He is also affiliated faculty at the Duke Global Health Institute, Duke Human Vaccine Institute, and University of Cape Town Department of Immunology. Dr. Ferrari has worked on testing samples from vaccine recipients for cytotoxic t lymphocyte (CTL) and antibody dependent cellular cytotoxic (ADCC) responses since 1995 initially for the AIDS Vaccine Evaluating Group (AVEG) and, subsequently for the HIV Vaccine Trial Network (HVTN) and worked as director of the ELISpot and, currently working as director of the ADCC laboratory. Dr. Ferrari was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses and the difference in class I-restricted epitope recognition between HIV-1 infected individuals and vaccine recipients. He followed this initial epitope mapping of cellular responses with the epitope mapping of ADCC responses. In 2011, he reported the anti-C1 epitope as the most recognized epitope by ADCC ab responses in infected individuals. Since 2005, Dr. Ferrari has been the director of the ADCC core laboratory for the comprehensive antibody-vaccine immune monitoring consortium directed by Dr. Montefiori; in 20011, he also joined the primate aids vaccine evaluation group (PAVEG) as director of the ADCC laboratory. Dr. Ferrari has gained a unique expertise in exploring the cytotoxic aspects of the anti-HIV-1 cellular and humoral immune responses.